2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1344 Efficacy and safety of direct oral anticoagulants compared with vitamin k antagonists and low molecular weight heparin in myeloproliferative neoplasm–associated splanchnic vein thrombosis: Analysis of gastro-mpn, an international cohort study

Pavlina Chrysafi, MD, Chi-Joan How, MD2, Amica K. Ko, MD, MSc3, Robert A. Redd4, Rebecca Zon, MD5, Damon E Houghton, MD, MS6, Atefeh Ghorbanzadeh7, Dahniel Sastow, MD8, Sai Alladi9, Maria Georgen10, Abi Prabhu11, Vrushali Pachpande, MD, MS12, Sai Valisekka, MBBS13, Balkrishna Jahagirdar14, Sargam Kapoor, MBBS15, Andrew Peseski, DO16, Radhika Gangaraju, MD, MSPH17, Ruchi Desai, MD18, Guoliang Zheng, MD19, Shreyash Dalmia, MD20, Vinai Bhagirath, MD, MSc, FRCPC21, Alejandro Godoy22, Alessandra Iurlo, MD23, Daniele Cattaneo, MD24, Paola Guglielmelli, MD, PhD25, Alessandro Vannucchi, MD26, Valentina Boldrini27, Valerio De Stefano28, Silvia Betti29, Elena Rossi, MD, PhD30, Walter Ageno, MD31, Jonathan Berry, MD32, Margherita Maffioli33, Mukul Agarwal, MD, DM34, Amiya Ranjan Nayak, MD, MBBS, DM35, Rishi Dhawan, 115033336, Thita Chiasakul, MD37, May Anne Cheong, MBBS38, Avi Leader, MD39, Kristen Marie Sanfilippo, MD, MPHS40, Douglas Tremblay, MD41, Gabriela Soriano Hobbs, MD42, Joan Denise Beckman, Lois, RichardKingAssistantProfessorandMcKnightLand-GrantProfessor43, Lisa Baumann Kreuziger, MD, MS44, Mandy N. Lauw, MD, PhD45, Rushad Patell, MD46
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Brigham and Women’s Hospital, Boston, Massachusetts, United States
3 Erasmus University Medical Center, Rotterdam, Netherlands
4 Dana-Farber Cancer Institute, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Mayo Clinic Comprehensive Cancer Center, Rochester, United States
7 Capital Health Regional Medical Center, Trenton, United States
8 Icahn School of Medicine at Mount Sinai, New York, United States
9 Mayo Clinic Comprehensive Cancer Center, Jacksonville, United States
10 Medical College of Wisconsin, Milwaukee, United States
11 University of Minnesota, Minneapolis, United States
12 University of Minnesota, Minneapolis, United States
13 University of Minnesota, Minneapolis, United States
14 University of Minnesota, Minneapolis, United States
15 Duke University, Durham, United States
16 Duke University, Durham, United States
17 University of Alabama at Birmingham, Birmingham, Alabama, United States
18 Virginia Commonwealth University, Richmond, United States
19 Virginia Commonwealth University, Richmond, United States
20 McMaster University, Hamilton, Ontario, Canada
21 McMaster University, Hamilton, Ontario, Canada
22 McMaster University, Hamilton, Ontario, Canada
23 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
24 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
25 University of Florence, Florence, Italy
26 University of Florence, Florence, Italy
27 University of Florence, Florence, Italy
28 Catholic University, Rome, Italy
29 Catholic University, Rome, Italy
30 Catholic University, Rome, Italy
31 University of Padova,, Padova, Italy
32 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
33 Hematology Unit, ASST Sette Laghi, Varese, Italy
34 All India Institute of Medical Sciences, New Delhi, India
35 All India Institute of Medical Sciences, New Delhi, India
36 All India Institute of Medical Sciences, New Delhi, India
37 Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
38 Singapore General Hospital, Singapore, Singapore
39 Memorial Sloan Kettering Cancer Center, New York, New York, United States
40 Washington University School of Medicine in St. Louis, St. Louis, United States
41 Icahn School of Medicine at Mount Sinai, New York, United States
42 Massachusetts General Brigham Cancer Institute, Boston, United States
43 University of Minnesota, Minneapolis, United States
44 Versiti, Milwaukee, United States
45 Erasmus University Medical Center, Rotterdam, Netherlands
46 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Background: Splanchnic vein thrombosis (SVT) occurs frequently in patients with myeloproliferative neoplasm (MPN), yet the optimal anticoagulant remains uncertain. Direct oral anticoagulants (DOAC) are increasingly used but comparative outcome data with vitamin K antagonists (VKA) and low-molecular-weight heparin (LMWH) are limited. Using the international, multicenter GASTRO-MPN cohort, we emulated target trials to characterize anticoagulant use and compare recurrent thrombosis, recanalization, and major bleeding across anticoagulants.

Methods: We included adults with imaging-confirmed SVT and an MPN diagnosed before or within 1 year after SVT. Anticoagulant and antiplatelet therapy were defined at a day-14 (D14) landmark after SVT diagnosis. The primary composite outcome was recurrent thrombosis, defined as recurrent/progressive SVT, extra-splanchnic venous thrombosis, or arterial thrombosis. Secondary outcomes were recurrent/progressive SVT individually, partial or complete radiographic recanalization, and major bleeding per ISTH definition. One-year cumulative incidence for all outcomes was estimated with death as a competing risk. We then emulated two target trials among patients anticoagulated at D14, using propensity score matching on age, sex, MPN type, JAK2 status, prior thrombosis, comorbidities, SVT site and D14 cytoreduction and antiplatelet treatment, to compare DOAC versus VKA and DOAC versus LMWH, separately. The primary intention-to-treat analysis estimated 1-year outcomes according to D14 anticoagulant assignment, regardless of subsequent switching or discontinuation. Sensitivity analyses censored treatment discontinuation, and a complementary per-protocol analysis modeled anticoagulant exposure as time-varying to account for switching.

Results: Among patients with MPN-SVT from 22 centers across 6 countries, this study focused on the 535 patients receiving anticoagulation at D14. Median age was 48 years (IQR, 37–62), 62% were female, and 41% had polycythemia vera, 25% essential thrombocythemia, 20% myelofibrosis, and 14% MPN-unclassifiable; 86% had a JAK2V617F mutation and MPN was newly diagnosed at or after the index SVT in 67%. SVT most often involved the portal (79%), followed by the splenic (43%), mesenteric (36%), and hepatic (21%) veins; 53% had multivessel involvement. At D14, 268 patients (50%) received VKA, 127 (24%) DOAC, 115 (22%) LMWH and 25 (5%) other anticoagulants; matched comparisons were restricted to the VKA, DOAC, and LMWH groups. At D14, 22% received concomitant antiplatelet therapy and 25% cytoreductive therapy. At 1 year, 76% remained on their initial anticoagulant, of which 84% were initially receiving VKA, 83% DOAC and 47% LMWH. Median follow-up was 1.9 years, recanalization assessment with follow-up imaging was available in 89% and 1-year overall survival was 95%.

After matching, covariates were balanced (standardized mean difference <0.2). In the DOAC–VKA comparison, DOAC were associated with lower 1-year recurrent thrombosis (7.8% [95% CI, 2.9–12.7] vs 12.8% [6.7–18.9]), similar recurrent/progressive SVT (3.6% [0.1–7.0] vs 4.3% [0.6–8.0]), higher recanalization (18.2% [11.1–25.3] vs 9.4% [4.1–14.7]), and higher major bleeding incidence (9.7% [4.2–15.2] vs 3.4% [0.1–6.8]). In the DOAC–LMWH comparison, DOAC were associated with lower recurrent thrombosis (5.9% [1.3–10.5] vs 15.7% [8.6–22.8]) and recurrent/progressive SVT (2.0% [0.0–4.6] vs 8.8% [3.3–14.3]), similar recanalization (17.9% [10.3–25.4] vs 19.7% [11.9–27.6]), but higher major bleeding incidence (11.1% [4.9–17.3] vs 4.8% [0.7–9.0]). Sensitivity analyses censoring treatment discontinuation were consistent. In per-protocol time-varying analyses, DOAC were associated with higher likelihood of recanalization than VKA (HR, 2.08; 95% CI, 1.32–3.33), without differences in recurrent thrombosis or major bleeding. Compared with LMWH, DOAC were associated with lower risk of recurrent thrombosis (HR, 0.49; 95% CI, 0.25–0.93) and recurrent/progressive SVT (HR, 0.33; 95% CI, 0.13–0.84), without differences in recanalization or major bleeding.

Conclusions: In this large international MPN-SVT cohort, DOAC were associated with lower incidence of recurrent thrombosis, particularly compared with LMWH, but more major bleeding than with VKA or LMWH. Recanalization was more frequent with DOAC than VKA but similar to LMWH. These findings suggest a potential benefit of DOACs in MPN-SVT but require confirmation in prospective studies.

Pavlina Chrysafi, MD: No relevant conflicts of interest to declare.